TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33225600
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 'any' analgesia
Study: 32949500
Drug: Intravesical Pyo
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical Pyo bacteriophage (Pyophage; 20 mL)
Study: 32949500
Drug: Intravesical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical placebo solution (20 mL)
Study: 32949500
Drug: Systemically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemically applied antibiotics
Study: 35803754
Drug: Bilateral single‐injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral single‐injection erector spinae plane block (ESPB) with ropivacaine 0.5%, 15 ml on each side
Study: 35803754
Drug: Bilateral single‐injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral single‐injection erector spinae plane block (ESPB)
Study: 35803754
Drug: Patient‐controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient‐controlled intravenous analgesia
Study: 33966019
Drug: Balanced colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced colloid (6% hydroxyethyl starch 130/0.4 in an isotonic solution)
Study: 32969548
Drug: Adjuvant radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant radiotherapy (aRT) administered on the tumour bed and pelvis within 6 months of RP.
Study: 32697031
Drug: Brief cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive-behavioural therapy (CBT-T)
Study: 32697031
Drug: Standard cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive-behavioural therapy (20 sessions)
Study: 32826769
Drug: Netarsudil 0.02%
Normalized name: NETARSUDIL 0.02% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netarsudil 0.02% once-daily
Study: 33389912
Drug: L-PRF application
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF application in extraction socket
Study: 34915492
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (with and without Docetaxel)
Study: 33591006
Drug: EA‐230 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA‐230 (90 mg/kg/hr)
Study: 34779583
Drug: LYT‐100 (deupirfenidone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYT‐100 (deupirfenidone) 100 mg twice daily
Study: 34779583
Drug: LYT‐100 (deupirfenidone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYT‐100 (deupirfenidone) 250 mg twice daily
Study: 34779583
Drug: LYT‐100 (deupirfenidone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYT‐100 (deupirfenidone) 500 mg twice daily
Study: 34779583
Drug: LYT‐100 (deupirfenidone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYT‐100 (deupirfenidone) 750 mg twice daily
Study: 34779583
Drug: LYT‐100 (deupirfenidone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYT‐100 (deupirfenidone) 1000 mg twice daily
Study: 34779583
Drug: LYT‐100 (deupirfenidone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYT‐100 (deupirfenidone) 500 mg single dose (fed condition)
Study: 34779583
Drug: LYT‐100 (deupirfenidone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYT‐100 (deupirfenidone) 500 mg single dose (fasting condition)
Study: 34779583
Drug: LYT‐100 (deupirfenidone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LYT‐100 (deupirfenidone) up to 1000 mg twice daily
Study: 32193992
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with a specific intervention (not specified)
Study: 34840031
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + AFO-202 beta glucan (n=8)
Study: 34840031
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + combination of AFO-202 and N-163 beta glucans (n=8)
Study: 34840031
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control group, n=8)
Study: 32831151
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (100 ml, twice a day for 7 days)
Study: 32831151
Drug: Saline (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (identical volume, twice a day for 7 days)
Study: 32831151
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection
Study: 34929690
Drug: Goal-directed care
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed care bundle (early intensive blood pressure lowering, glycaemic control, treatment of pyrexia, and reversal of anticoagulation)
Study: 36202236
Drug: COVID-19 vaccine
Normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccine message group
Study: 34459398
Drug: Insulin‐like growth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin‐like growth factor‐binding protein 2 (AD APOE‐ PRS)
Study: 33039390
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for pelvic organ prolapse
Study: 34028358
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (14 weeks, therapist-guided)
Study: 32338459
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg generic dabigatran etexilate capsule (test drug)
Study: 32338459
Drug: Commercial dabigatran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial dabigatran etexilate capsule (Pradaxa® , reference drug)
Study: 34820856
Drug: >20 cc/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: >20 cc/kg volume of leukoreduced RBC transfusions
Study: 38212068
Drug: Selective Internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Internal Radiation Therapy (SIRT)
Study: 34848312
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (1 µg.kg‐1 loading, 0.6 µg.kg‐1.h‐1 infusion)
Study: 34848312
Drug: Lignocaine-dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine-dexmedetomidine infusion (1.5 mg.kg‐1 loading, 2 mg.kg‐1.h‐1 infusion and 1 µg.kg‐1 loading, 0.5 µg.kg‐1.h‐1 infusion)
Study: 34848312
Drug: Lignocaine infusion
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine infusion (1.5 mg.kg‐1 loading, 2 mg.kg‐1.h‐1 infusion)
Study: 34848312
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (10 mL loading, 1 mL.kg‐1.h‐1 infusion)
Study: 33171597
Drug: Korean Red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng (2 g once daily)
Study: 33171597
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 g once daily)
Study: 34086485
Drug: Technology-facilitated self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technology-facilitated self-management support with weekly automated interactive voice response telephone calls for 12 months
Study: 36350359
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D intake from supplements
Study: 34001024
Drug: Ambient bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambient bright light treatment (1000 lx, 6000 K from 10:00 to 15:00)
Study: 32787848
Drug: Vaginally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginally administered conjugated estrogens tablet (0.625 mg, daily for 3 weeks then twice weekly for 9 weeks)
Study: 33735517
Drug: Biofeedback relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback relaxation (BR) during LA administration
Study: 33735517
Drug: Audio-visual (AV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audio-visual (AV) distraction during LA administration
Study: 32115032
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of NAM (50 mg/kg)
Study: 32115032
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of NAM (100 mg/kg)
Study: 32115032
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of BA (500 mg/kg)
Study: 32115032
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of BA (1,000 mg/kg)
Study: 32115032
Drug: Compound supplement
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound supplement (50 mg/kg NAM + 500 mg/kg BA)
Study: 34070910
Drug: Oral native
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral native vitamin D3 at a dose of 2000 IU once a day for 12 months
Study: 34555481
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose secukinumab (75/75/150 mg)
Study: 34555481
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose secukinumab (75/150/300 mg)
Study: 33762414
Drug: Recombinant adjuvanted
Normalized name: zoster vaccine, recombinant adjuvanted intramuscular powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adjuvanted vaccine (RZV)
Study: 33762414
Drug: Live-attenuated vaccine
Normalized name: Chikungunya vaccine (live, attenuated)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated vaccine (ZVL)
Study: 32706681
Drug: Lottery incentive
Normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [BEACH DREAM GLITTERY SUNSCREEN SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lottery incentive (US $50 weekly lottery drawing)
Study: 32401873
Drug: Rothbaum cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rothbaum cognitive behavioral therapy protocol (individual treatment)
Study: 32401873
Drug: Rothbaum cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rothbaum cognitive behavioral therapy protocol (group treatment)
Study: 32401873
Drug: Rothbaum cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rothbaum cognitive behavioral therapy protocol (both individual and group formats)
Study: 35346332
Drug: Levetiracetam plus
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam plus temozolomide chemotherapy for 34 weeks
Study: 35346332
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets plus temozolomide for 34 weeks
Study: 32585438
Drug: In-bed cycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-bed cycling (30 min daily) in addition to usual-care physiotherapy
Study: 33028675
Drug: Baricitinib (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (once-daily oral dosing)
Study: 34773803
Drug: Berberine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine (900 mg per day)
Study: 32599716
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.0055 g·kg−1 post training set)
Study: 32599716
Drug: Placebo (0.0055
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.0055 g·kg−1 post training set)
Study: 35157829
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg orally twice daily for 24 weeks
Study: 32972289
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral clarithromycin twice a day
Study: 32972289
Drug: 20 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg/day systematic glucantime
Study: 32691120
Drug: Tramadol 100
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 100 mg orally
Study: 32691120
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg orally
Study: 34326131
Drug: GEN-1 (IL12
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEN-1 (IL12 plasmid) administered in eight weekly intraperitoneal infusions starting at cycle 1 week 2 in combination with three 21-day cycles of NACT carboplatin AUC 6 and weekly paclitaxel 80 mg/m2
Study: 34326131
Drug: NACT carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NACT carboplatin AUC 6 and weekly paclitaxel 80 mg/m2
Study: 34939363
Drug: Jujube syrup
Normalized name: JUJUBE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jujube syrup (10 cc per day)
Study: 34939363
Drug: Placebo syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo syrup (10 cc per day)
Study: 35451020
Drug: 25% dextrose
Normalized name: Delflex with 4.25% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% dextrose (0.5 mL orally)
Study: 35451020
Drug: 24% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% sucrose (0.5 mL orally)
Study: 33667495
Drug: Nasal nocturnal
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nasal nocturnal oxygen supplementation (NOS) at 2 L/min
Study: 32044621
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 50 mg plus Hyoscine‐N‐Butylbromide 10 mg
Study: 35293520
Drug: CBD (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (300 mg)
Study: 32186246
Drug: Multicap (capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicap (capsule containing aspirin, atenolol, ramipril, and simvastatin)
Study: 32186246
Drug: Control (separate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (separate pills for each drug)
Study: 33251914
Drug: Early-initiated oral
Normalized name: valbenazine
DrugBank: Valbenazine (DB11915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early-initiated oral anticoagulation (OAC) prescribed within 30 days after surgery to 1,770 patients (24.0% of those with POAF)
Study: 33640067
Drug: Screening plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening plus Eave Tubes (10% wettable powder formulation of β‐cyfluthrin)
Study: 36038881
Drug: Daily Caloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Caloric Restriction (DCR)
Study: 35404015
Drug: DS-8895a at
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8895a at 1 mg/kg (Cohort 1)
Study: 35404015
Drug: DS-8895a at
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8895a at 3 mg/kg (Cohort 2)
Study: 36364963
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy (protein 1.2−1.5 g/kg) and probiotics for two months
Study: 36364963
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without diet therapy and probiotics
Study: 33076888
Drug: Corticosteroid trigger
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid trigger point injection (TPI)
Study: 32965160
Drug: Sinusoidal linear
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinusoidal linear accelerations ranging from 0.03 Hz at 0.5 mG to 0.2 Hz at 5 mG
Study: 33350787
Drug: ASF (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASF (a Compound of Traditional Chinese Medicine)
Study: 34182873
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200 mg daily from 16 to 33 weeks of gestation)
Study: 35358063
Drug: Gabapentin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (50 mg/kg)
Study: 33218742
Drug: Naltrexone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone + Bupropion (NB) 50/300 mg
Study: 35556946
Drug: MitoQ (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoQ (100 - 160 mg based on body mass)
Study: 33639922
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (tailored group classes twice a week for 16 weeks)
Study: 33123119
Drug: Pandemic adjuvanted
Normalized name: pangamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pandemic adjuvanted vaccine
Study: 33123119
Drug: One vaccination
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vaccination dose
Study: 33123119
Drug: Two vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two vaccination doses
Study: 33123119
Drug: Pre-existing antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-existing antibodies before vaccination
Study: 33123119
Drug: De novo
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De novo anti-HLA antibodies
Study: 35073492
Drug: Tinnitus Retraining
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus Retraining Therapy (TRT; counseling and conventional sound generators)
Study: 35073492
Drug: Partial Tinnitus
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial Tinnitus Retraining Therapy (pTRT; counseling and placebo sound generators)
Study: 34121308
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (Lantus®)
Study: 32179562
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry juice daily for a 12-month period
Study: 32403118
Drug: POMA 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: POMA 320 mg/d
Study: 32403118
Drug: POMA 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: POMA 80 mg/d
Study: 32403118
Drug: TS-134 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-134 20 mg/d
Study: 32403118
Drug: TS-134 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-134 60 mg/d
Study: 34307079
Drug: PROB 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROB 3 (3 ml of probiotic)
Study: 34307079
Drug: PROB 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROB 2 (2 ml of probiotic)
Study: 32217809
Drug: Pasireotide 40
Normalized name: pasireotide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 40 or 60 mg
Study: 32217809
Drug: Pasireotide 60
Normalized name: pasireotide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 60 mg (for uncontrolled patients)
Study: 32185729
Drug: VisuEvo® (self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: VisuEvo® (self-administered three times daily for the whole study duration)
Study: 32185729
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no tear substitute administration)
Study: 33091202
Drug: 1.8% liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8% liposomal TA twice daily
Study: 33091202
Drug: Microneedling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling with 5% TA solution weekly
Study: 34678908
Drug: Shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu injection (SFI) + azithromycin + 100 mL 5% glucose injection
Study: 34678908
Drug: azithromycin +
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin + 150 mL 5% glucose injection
Study: 32747522
Drug: Fremanezumab quarterly
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab quarterly or monthly
Study: 35865278
Drug: Raising Our
Normalized name: cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raising Our Spirits Together (ROST), a technology‐assisted cognitive behavioral therapy (T‐CBT) for depression, delivered virtually in a small group format across 8 weekly sessions via videoconferencing software.
Study: 35276897
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of Medium-Chain Triglycerides (MCTs) daily for 2 weeks
Study: 33373464
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg 3 times daily for 3 days, then placebo for 4 days)
Study: 33373464
Drug: Ibuprofen (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (3 times daily for 7 days)
Study: 32831133
Drug: Adjunct therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct therapeutic plasma exchange (TPE)
Study: 32567124
Drug: Oral PALO
Normalized name: palo verde pollen extract
DrugBank: Parkinsonia florida pollen (DB11006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PALO 0.50 mg
Study: 32567124
Drug: IV PALO
Normalized name: palo verde pollen extract
DrugBank: Parkinsonia florida pollen (DB11006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV PALO 0.25 mg
Study: 36109791
Drug: Carrageenan nasal
Normalized name: Carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrageenan nasal and throat spray (1.2 mg iota-carrageenan, 0.4 mg kappa-carrageenan, 0.5% sodium chloride) applied daily for 8 weeks
Study: 36109791
Drug: Placebo (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5% sodium chloride) applied daily for 8 weeks
Study: 36109791
Drug: Carrageenan nasal
Normalized name: Carrageenan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrageenan nasal and throat spray
Study: 33069664
Drug: Caffeine dose
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine dose > 1.3 mg/kg
Study: 32213484
Drug: Self-managed, computerised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-managed, computerised speech and language therapy
Study: 35851035
Drug: nHF 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: nHF 6 L/min
Study: 34969712
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 for 6 cycles (Arm A)
Study: 35047809
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (6-week cast immobilization)
Study: 36219303
Drug: Self-monitoring plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring plus self-titration of antihypertensive medication
Study: 32401557
Drug: individual child-focused
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: individual child-focused cognitive behavioral therapy (CBT)
Study: 36450540
Drug: Agent balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent balloon coated with a low-dose formulation of paclitaxel (2 μg/mm2)